{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-007574","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.621174+00:00","generated_at":"2026-05-21T12:56:18.737960+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Capricor Q1 net loss $24.4M; deramiocel BLA PDUFA Aug 31, 2025","bullets":["Net loss of $24.4M ($0.53/sh) vs $9.8M loss ($0.31/sh) in Q1 2024; revenue $0 vs $4.9M.","Cash and equivalents $144.8M as of Mar 31, 2025; expected to fund operations into 2027.","FDA accepted BLA for deramiocel in DMD-cardiomyopathy with priority review; PDUFA date Aug 31, 2025.","Mid-cycle review with FDA completed; no significant deficiencies identified; advisory committee planned.","Appointed Dr. Michael Binks as CMO; NIAID plans to initiate StealthX vaccine Phase 1 trial in Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-007574","json":"https://secwatch.observer/filing/0001558370-25-007574.json","markdown":"https://secwatch.observer/filing/0001558370-25-007574.md","text":"https://secwatch.observer/filing/0001558370-25-007574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837025007574/0001558370-25-007574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837025007574/capr-20250513x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T12:56:18.737960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}